934175-49-2

Usage

Uses

Used in Pharmaceutical Research:
2-(1H-pyrazol-1-yl)acetohydrazide(SALTDATA: FREE) is used as a key intermediate in the synthesis of various pharmaceutical compounds for its versatile chemical properties and potential therapeutic effects.
Used in Anti-inflammatory Applications:
In the medical industry, 2-(1H-pyrazol-1-yl)acetohydrazide(SALTDATA: FREE) is used as an anti-inflammatory agent to help reduce inflammation and associated symptoms.
Used in Analgesic Applications:
2-(1H-pyrazol-1-yl)acetohydrazide(SALTDATA: FREE) is utilized as an analgesic to alleviate pain, providing relief to patients suffering from various conditions.
Used in Antipyretic Applications:
2-(1H-pyrazol-1-yl)acetohydrazide(SALTDATA: FREE) is used as an antipyretic to reduce fever and associated discomfort.
Used in Cancer Treatment Research:
In oncology, 2-(1H-pyrazol-1-yl)acetohydrazide(SALTDATA: FREE) is being investigated for its potential role in the treatment of cancer, targeting various types of cancer cells.
Used in Neurodegenerative Disorder Treatment Research:
2-(1H-pyrazol-1-yl)acetohydrazide(SALTDATA: FREE) is being studied for its possible applications in treating neurodegenerative disorders, aiming to provide therapeutic benefits to patients with such conditions.
Used in Antimicrobial Applications:
In the field of microbiology, 2-(1H-pyrazol-1-yl)acetohydrazide(SALTDATA: FREE) is used as an antimicrobial agent to inhibit the growth of certain bacteria.
Used in Antiviral Applications:
2-(1H-pyrazol-1-yl)acetohydrazide(SALTDATA: FREE) is being explored for its potential as an antiviral agent, showing promise in inhibiting the growth of specific viruses.

Upstream product

• 10199-61-8 pyrazol-1-yl acetic acid ethyl ester 

Relevant academic research and scientific papers

Antimicrobial Evaluation, Synthesis, and Characterization of Some 1-(5-((1H-Pyrazol-1-yl)methyl)-2-aryl-1,3,4-oxadiazol-3(2H)-yl)ethanone Derivatives

Ethyl 2-(1H-pyrazol-1-yl)acetate (1) was synthesized by the reaction of ethyl chloro acetate with 1H-pyrazole. Compound (1) was refluxed with hydrazine hydrate to get 2-(1H-pyrazol-1-yl) acetohydrazide (2). N'-arylidine-2-(1H-pyrazol-1-yl)acetohydrazide d

7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS

Compounds of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, their preparation, and use in treating a bacterial infection are disclosed.

Synthesis of N- and C-azolyl-substituted pyrazolo[1,5-a]pyrimidines by recyclization of pyrimidinium salts

We studied the reaction of 2-(ethoxycarbonyl)methyl-1,4,6-trimethylpyrimidinium iodide with hydrazides of N-azolyl- and C-pyrazolyl-substituted carboxylic acids, which were synthesized by reacting the respective esters with hydrazine hydrate. This reaction was shown to result in recyclization and formation of ethyl 2-(pyrazolylalkyl)- and 2-(azolylalkyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine- 3-carboxylates. Besides pyrazolopyrimidines, the separation of reaction mixture provided in some cases also another recyclization product, 2-hydroxy-5,7-dimethylpyrazolo[1,5-a]pyrimidine.

Tetrazolylhydrazides as selective fragment-like inhibitors of the JumonjiC-domain-containing histone demethylase KDM4A

The JumonjiC-domain-containing histone demethylase 2A (JMJD2A, KDM4A) is a key player in the epigenetic regulation of gene expression. Previous publications have shown that both elevated and lowered enzyme levels are associated with certain types of cancer, and therefore the definite role of KDM4A in oncogenesis remains elusive. To identify a novel molecular starting point with favorable physicochemical properties for the investigation of the physiological role of KDM4A, we screened a number of molecules bearing an iron-chelating moiety by using two independent assays. In this way, we were able to identify 2-(1H-tetrazol-5-yl)acetohydrazide as a novel fragment-like lead structure with low relative molecular mass (Mr=142 Da), low complexity, and an IC50 value of 46.6 μm in a formaldehyde dehydrogenase (FDH)-coupled assay and 2.4 μm in an antibody-based assay. Despite its small size, relative selectivity against two other demethylases could be demonstrated for this compound. This is the first example of a tetrazole group as a warhead in JMJD demethylases. Anchor fragment: To develop non-promiscuous metalloenzyme inhibitors, a metal-complexing acetohydrazide group was integrated in a tetrazolyl fragment, which can be matured into a scaffold to promote further selectivity at the ligand backbone binding site of these emerging drug targets.